Open Payments Disclosure

Telegenix is committed to transparency in the financial relationships between our physicians and the manufacturers of the medications and devices we prescribe. This disclosure is provided in compliance with Section 6002 of the Patient Protection and Affordable Care Act ("the Physician Payments Sunshine Act") and 42 C.F.R. Part 403, Subpart I. OUR POSITION No Telegenix physician receives payment, gifts, meals, honoraria, consulting fees, or other transfers of value from any pharmaceutical manufacturer or medical device company in exchange for prescribing a specific medication. Our physicians are independent contractors compensated solely by Telegenix for clinical services rendered, and Telegenix does not condition that compensation on prescribing volumes or formulary choices. Telegenix itself does not accept rebates, advertising fees, or volume incentives from any manufacturer in exchange for promoting a specific medication on this platform. Our clinical protocols are developed by our medical advisory team based on clinical evidence, peer-reviewed literature, and applicable FDA labeling — not on commercial relationships. WHAT GETS REPORTED Under the Sunshine Act, applicable manufacturers and group purchasing organizations are required to report most payments and transfers of value to covered recipients (including physicians) to the Centers for Medicare & Medicaid Services ("CMS"). Telegenix supports this reporting by maintaining the records each manufacturer requests. WHERE TO LOOK You can review reported payments to any U.S. physician on the federal Open Payments database, maintained by CMS: https://openpaymentsdata.cms.gov Search by physician name or NPI to see any reported payment. REPORTING CONCERNS If you believe you have observed undisclosed financial conflicts or pressure to prescribe a specific medication, report your concern to compliance@telegenix.com. Reports may be made anonymously. Telegenix will investigate every credible report and take appropriate action, including termination of relationships where warranted. PLACEHOLDER — this draft is provided for Aftershock QA and client review. Final disclosure language must be confirmed by Telegenix's counsel and Compliance Officer before launch.